¼¼°èÀÇ È£Èí±â Áúȯ °Ë»ç ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× ¿¹Ãø(2025-2032³â)
Respiratory Disease Testing Market, By Product, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1684425
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 322 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,612,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,598,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,017,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

È£Èí±â Áúȯ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â 65¾ï 9,043¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2032³â ¿¬Æò±Õ 2.99% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

È£Èí±â Áúȯ °Ë»ç ½ÃÀå ¿ªÇÐ

°¨¿°¼º È£Èí±â ÁúȯÀÇ È®»ê°ú µðÁöÅÐ ÅëÇÕ Áõ°¡·Î ½ÃÀå ¼ö¿ä Áõ°¡ Àü¸Á

È£Èí±â Áúȯ °Ë»ç ½ÃÀåÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±â¼ú ¹ßÀü µî ´Ù¾çÇÑ ¿äÀÎÀÌ °ãÄ¡¸é¼­ Å« ÆøÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), °£Áú¼ºÆóÁúȯ µî ¸¸¼º È£Èí±â ÁúȯÀº Áõ°¡ Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é COPD´Â Àü ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀ̸ç, õ½ÄÀº Àü ¼¼°è ¼ö¾ï ¸íÀÌ ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, RT-PCR°ú °°Àº ½Å¼Ó °Ë»ç¹ýÀÌ ÀϹÝÈ­µÇ¸é¼­ Áø´Ü ½ÇÇè½ÇÀº ±× ¿ª·®À» È®ÀåÇß½À´Ï´Ù.

¶ÇÇÑ, ºÐÀÚÁø´ÜÇÐ, ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) °Ë»ç, Â÷¼¼´ë¿°±â¼­¿­ºÐ¼®(NGS) µîÀÇ »õ·Î¿î ±â¼úÀº È£Èí±â ÁúȯÀÇ °ËÃ⠹ਵµ¿Í ƯÀ̼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ÈÞ´ë°¡ °¡´ÉÇÏ°í ½Å¼ÓÇÑ Áø´Ü µµ±¸ÀÇ µîÀåÀ¸·Î È£Èí±â Áúȯ °Ë»ç°¡ ´õ¿í Ä£¼÷ÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ¿ø°ÝÁö³ª ÀÀ±Þ»óȲ¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)ÀÌ Áø´Ü ÇÁ·Î¼¼½º¿¡ ÅëÇÕµÇ¾î ¼Óµµ¿Í Á¤È®µµ°¡ Çâ»óµÇ°í ÀÖÀ¸¸ç, AI ±â¹Ý µµ±¸´Â ÈäºÎ ¿¢½º·¹ÀÌ ¹× CT ½ºÄµ°ú °°Àº ¿µ»ó °Ë»çÀÇ ÇØ¼®À» µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °í±Þ Áø´Ü µµ±¸ÀÇ ³ôÀº ºñ¿ë°ú ÀÇ·á Á¢±Ù¼º °ÝÂ÷´Â ¿ø°Ý ÀÇ·á ¹× Àúºñ¿ë °Ë»ç ¼Ö·ç¼Ç°ú °°Àº ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ¿© ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

È£Èí±â Áúȯ °Ë»ç ½ÃÀå : ÁÖ¿ä °íÂû

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 2.99%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç°º°·Î´Â ¿¢½º·¹ÀÌ ¿µ»ó äÅà Áõ°¡·Î ÀÎÇØ ¿µ»ó °Ë»ç ºÎ¹®ÀÌ 2024³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î´Â °áÇÙÀÇ ³ôÀº À¯º´·ü°ú Áø´ÜÀÇ Çʿ伺 ¶§¹®¿¡ °áÇÙ ºÐ¾ß°¡ 2024³â ÁÖ¿ä ¿ëµµ ºÐ¾ß°¡ µÇ¾ú½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â ¿¢½º·¹ÀÌ Àåºñ¿Í °°Àº ÷´Ü ÀÇ·á±â±âÀÇ µµÀÔÀÌ Áõ°¡ÇÔ¿¡ µû¶ó 2024³â¿¡´Â º´¿ø ºÐ¾ß°¡ ÃÖÁ¾ »ç¿ëÀÚ ºÐ¾ß¿¡¼­ ¼±µÎ¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº°·Î´Â õ½Ä ¹× ±âŸ È£Èí±â ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ºÏ¹Ì°¡ 2024³â ÁÖ¿ä ¼öÀÍ¿øÀÌ µÇ¾ú½À´Ï´Ù.

È£Èí±â Áúȯ °Ë»ç ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

È£Èí±â Áúȯ °Ë»ç ¼¼°è ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç°º°·Î´Â ¿µ»ó °Ë»ç, Ç÷¾×°¡½º °Ë»ç, È£Èí±â ÃøÁ¤ ÀåÄ¡, ±âŸ µî 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. ¿µ»ó °Ë»ç ºÐ¾ß°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, X¼± Àåºñ ¹× 3D ¿µ»ó Ç÷§Æû°ú °°Àº ÷´Ü ¿µ»ó ÀåºñÀÇ ³ôÀº µµÀÔÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¿ëµµº°·Î Æó¾Ï, °áÇÙ, õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ±âŸ µî 5°¡Áö·Î ºÐ·ùµË´Ï´Ù. °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÏ´Â °ÍÀº °áÇÙÀÔ´Ï´Ù. Æó¾Ï ºÎ¹®Àº ¿¹¹æ Áø´Ü Ä¡·áÀÇ Çʿ伺À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿ø, ÀÓ»ó ½ÇÇè½Ç, ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â º´¿ø ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÷´Ü Àåºñ¸¦ ÅëÇÑ È¯ÀÚ Áø´Ü¿¡ ´ëÇÑ ³ôÀº ¿ä±¸°¡ ÀÌ ºÎ¹® ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

È£Èí±â Áúȯ °Ë»ç ½ÃÀå : Áö¿ªº° ºÐ¼®

È£Èí±â Áúȯ °Ë»ç ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ °ÉÃÄ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ºÏ¹Ì°¡ ¼¼°è È£Èí±â Áúȯ °Ë»ç ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ´Â °ÍÀº ¼±ÁøÀûÀÎ ÇコÄɾî ÀÎÇÁ¶ó, ÷´Ü Áø´Ü¹ýÀÇ ³ôÀº äÅ÷ü, °­·ÂÇÑ R&D ÅõÀÚ¿¡ ±âÀÎÇÕ´Ï´Ù. ¹Ì±¹ ÆóÇùȸ¿¡ µû¸£¸é 2023³â¿¡´Â ¾à 1,600¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ COPD Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¸¹Àº ȯÀÚ Àα¸, ÀÇ·á ÀÎÇÁ¶ó °³¼±, ÅõÀÚ Áõ°¡·Î ÀÎÇØ È£Èí±â Áúȯ °Ë»ç ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹À̳ª Àεµ¿Í °°Àº ±¹°¡µéÀº °øÇØ¿Í Èí¿¬ µîÀ¸·Î ÀÎÇØ °áÇÙ(TB), COPD, ±âŸ È£Èí±â °¨¿°ÁõÀÇ ¹ßº´·üÀÌ ³ô½À´Ï´Ù.

È£Èí±â Áúȯ °Ë»ç ½ÃÀå : °æÀï ±¸µµ

È£Èí±â Áúȯ °Ë»ç ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ´Ù¾çÇÑ Áø´Ü ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ¼¼°è ±â¾÷, Áö¿ª ±â¾÷, ½ºÅ¸Æ®¾÷ÀÌ Á¸ÀçÇÕ´Ï´Ù. °æÀïÀº ¼±ÁøÀûÀ̰í Á¤È®ÇÏ°í ºü¸¥ °Ë»ç¹ý¿¡ ´ëÇÑ ´ÏÁî¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï±¹¿¡¼­´Â ½ºÅ¸Æ®¾÷°ú Áß¼Ò±â¾÷ÀÌ ÈÞ´ë °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» µµÀÔÇÏ¿© ±â¼ú Çõ½Å¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå °ü°èÀÚµéÀº °áÇÙ ¹× Æó·Å°ú °°Àº È£Èí±â °¨¿°¿¡ ´ëÇÑ ¹Ì»ý¹°ÇÐ ¹× ºÐÀÚ»ý¹°ÇÐÀû Áø´Ü¹ý¿¡µµ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. °¢ ¾÷üµéÀº ÀÇ·áÁø°ú ȯÀÚµéÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ Çõ½ÅÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀ» µµÀÔÇϱâ À§ÇÑ ¿¬±¸°³¹ß¿¡ Àû±Ø ³ª¼­°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå È£Èí±â Áúȯ °Ë»ç ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå ±¸µµ

Á¦7Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå : Á¦Ç°º°

Á¦8Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå : ¿ëµµº°

Á¦9Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå È£Èí±â Áúȯ °Ë»ç ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : È£Èí±â Áúȯ °Ë»ç ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Respiratory Disease Testing Market size was valued at USD 6,590.43 Million in 2024, expanding at a CAGR of 2.99% from 2025 to 2032.

Respiratory disease testing is used in diagnostic procedures to detect, evaluate, and monitor diseases affecting the respiratory system, which includes the lungs, airways, and other structures involved in breathing. These tests help identify conditions such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis, lung cancer, and infections like COVID-19 virus.

Respiratory Disease Testing Market- Market Dynamics

Growing prevalence of infectious respiratory diseases and rising digital integration are expected to propel market demand

The respiratory disease testing market has is expected to witness substantial growth due to a combination of factors, including the rising prevalence of respiratory illnesses, and technological advancements. Chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases are on the rise. According to the World Health Organization (WHO), COPD is among the leading causes of death worldwide, and asthma affects hundreds of millions worldwide. Further, rapid testing methods like RT-PCR became household terms, and diagnostic labs expanded their capacity.

Furthermore, New techniques, such as molecular diagnostics, polymerase chain reaction (PCR) tests, and next-generation sequencing (NGS), have improved the sensitivity and specificity of respiratory disease detection. The availability of portable and rapid diagnostic tools has made respiratory disease testing more accessible. These devices are particularly beneficial in remote areas and emergency scenarios. Artificial intelligence (AI) and machine learning (ML) are being integrated into diagnostic processes to enhance speed and accuracy. AI-powered tools are aiding in the interpretation of imaging tests like chest X-rays and CT scans. Moreover, high costs of advanced diagnostic tools and disparities in healthcare access, these issues have prompted innovations like telemedicine and low-cost testing solutions, further driving growth.

Respiratory Disease Testing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.99% over the forecast period (2025-2032)

Based on Product segmentation, the imaging tests segment was predicted to show maximum market share in the year 2024, due to increased adoption of X-ray imaging.

Based on Application segmentation, the tuberculosis segment was the leading Application segment in 2024, due to high prevalence of tuberculosis and need for diagnosis.

Based on End User segmentation, the hospitals segment was the leading End User segment in 2024, due to increasing adoption of advanced medical devices like X-ray machines.

On the basis of region, North America was the leading revenue generator in 2024, owing to high prevalence of asthma, and other respiratory diseases.

Respiratory Disease Testing Market- Segmentation Analysis:

The Global Respiratory Disease Testing Market is segmented on the basis of Product, Application, End User, and Region.

The market is divided into four categories based on Product: imaging tests, blood gas test, respiratory measurement devices, and others. The imaging tests segment dominates the market. High adoption of advanced imaging devices like X-ray machines and 3D imaging platforms are fueling segment growth.

The market is divided into five categories based on the Application: lung cancer, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), and others. The tuberculosis segment is expected to hold the largest share. The lung cancer segment is estimated to grow at the fastest rate during the forecast period, due to the need for preventive diagnosis care.

The market is divided into three categories based on End User: hospitals, clinical laboratories, and others. The hospitals segment holds the largest share in the End User segment. The growing prevalence of respiratory diseases, and high need for patient diagnosis with advanced devices is contributing to segment demand.

Respiratory Disease Testing Market- Geographical Insights

Across the world, the Respiratory Disease Testing market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a significant share of the global respiratory disease testing market due to its advanced healthcare infrastructure, high adoption of advanced diagnostics, and strong R&D investments. According to the American Lung Association, approximately 16 million Americans are diagnosed with COPD in 2023. The Asia-Pacific region is expected to witness the highest growth in the respiratory disease testing market due to a large patient population, improving healthcare infrastructure, and increased investments. Countries like China and India have high rates of tuberculosis (TB), COPD, and other respiratory infections due to pollution, smoking, etc.

Respiratory Disease Testing Market- Competitive Landscape:

The respiratory disease testing market is highly competitive, with the presence of global, regional, and emerging players offering a range of diagnostic solutions. Competition is fueled by the need for advanced, accurate, and rapid testing methods. In emerging economies, startups and smaller firms are contributing to innovation by introducing portable and cost-effective solutions. Market players also focus on microbiology and molecular diagnostics for respiratory infections like tuberculosis and pneumonia. Companies are actively engaged in research and development to introduce innovative diagnostic solutions to meet the evolving needs of healthcare providers and patients.

Recent Developments:

In October 2024, Quest Diagnostics announced the launch of a test for the H5N1 bird flu, to enhance the company's portfolio.

In October 2024, Oxford Nanopore partnered with NHS England to expedite the screening of new pathogens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY DISEASE TESTING MARKET KEY PLAYERS

GLOBAL RESPIRATORY DISEASE TESTING MARKET, BY PRODUCT- MARKET ANALYSIS, 2019-2032

GLOBAL RESPIRATORY DISEASE TESTING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

GLOBAL RESPIRATORY DISEASE TESTING MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

GLOBAL RESPIRATORY DISEASE TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Respiratory Disease Testing Market Overview

2. Executive Summary

3. Respiratory Disease Testing Key Market Trends

4. Respiratory Disease Testing Industry Study

5. Respiratory Disease Testing Market: Impact of Escalating Geopolitical Tensions

6. Respiratory Disease Testing Market Landscape

7. Respiratory Disease Testing Market - By Product

8. Respiratory Disease Testing Market - By Application

9. Respiratory Disease Testing Market - By End User

10. Respiratory Disease Testing Market- By Geography

11. Key Vendor Analysis- Respiratory Disease Testing Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â